Cargando…
Cancer Vaccine by Fusions of Dendritic and Cancer Cells
Dendritic cells (DCs) are potent antigen-presenting cells and play a central role in the initiation and regulation of primary immune responses. Therefore, their use for the active immunotherapy against cancers has been studied with considerable interest. The fusion of DCs with whole tumor cells repr...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2825547/ https://www.ncbi.nlm.nih.gov/pubmed/20182533 http://dx.doi.org/10.1155/2009/657369 |
_version_ | 1782177822489444352 |
---|---|
author | Koido, Shigeo Hara, Eiichi Homma, Sadamu Namiki, Yoshihisa Ohkusa, Toshifumi Gong, Jianlin Tajiri, Hisao |
author_facet | Koido, Shigeo Hara, Eiichi Homma, Sadamu Namiki, Yoshihisa Ohkusa, Toshifumi Gong, Jianlin Tajiri, Hisao |
author_sort | Koido, Shigeo |
collection | PubMed |
description | Dendritic cells (DCs) are potent antigen-presenting cells and play a central role in the initiation and regulation of primary immune responses. Therefore, their use for the active immunotherapy against cancers has been studied with considerable interest. The fusion of DCs with whole tumor cells represents in many ways an ideal approach to deliver, process, and subsequently present a broad array of tumor-associated antigens, including those yet to be unidentified, in the context of DCs-derived costimulatory molecules. DCs/tumor fusion vaccine stimulates potent antitumor immunity in the animal tumor models. In the human studies, T cells stimulated by DC/tumor fusion cells are effective in lysis of tumor cells that are used as the fusion partner. In the clinical trials, clinical and immunological responses were observed in patients with advanced stage of malignant tumors after being vaccinated with DC/tumor fusion cells, although the antitumor effect is not as vigorous as in the animal tumor models. This review summarizes recent advances in concepts and techniques that are providing new impulses to DCs/tumor fusions-based cancer vaccination. |
format | Text |
id | pubmed-2825547 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-28255472010-02-24 Cancer Vaccine by Fusions of Dendritic and Cancer Cells Koido, Shigeo Hara, Eiichi Homma, Sadamu Namiki, Yoshihisa Ohkusa, Toshifumi Gong, Jianlin Tajiri, Hisao Clin Dev Immunol Review Article Dendritic cells (DCs) are potent antigen-presenting cells and play a central role in the initiation and regulation of primary immune responses. Therefore, their use for the active immunotherapy against cancers has been studied with considerable interest. The fusion of DCs with whole tumor cells represents in many ways an ideal approach to deliver, process, and subsequently present a broad array of tumor-associated antigens, including those yet to be unidentified, in the context of DCs-derived costimulatory molecules. DCs/tumor fusion vaccine stimulates potent antitumor immunity in the animal tumor models. In the human studies, T cells stimulated by DC/tumor fusion cells are effective in lysis of tumor cells that are used as the fusion partner. In the clinical trials, clinical and immunological responses were observed in patients with advanced stage of malignant tumors after being vaccinated with DC/tumor fusion cells, although the antitumor effect is not as vigorous as in the animal tumor models. This review summarizes recent advances in concepts and techniques that are providing new impulses to DCs/tumor fusions-based cancer vaccination. Hindawi Publishing Corporation 2009 2010-02-18 /pmc/articles/PMC2825547/ /pubmed/20182533 http://dx.doi.org/10.1155/2009/657369 Text en Copyright © 2009 Shigeo Koido et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Koido, Shigeo Hara, Eiichi Homma, Sadamu Namiki, Yoshihisa Ohkusa, Toshifumi Gong, Jianlin Tajiri, Hisao Cancer Vaccine by Fusions of Dendritic and Cancer Cells |
title | Cancer Vaccine by Fusions of Dendritic and Cancer Cells |
title_full | Cancer Vaccine by Fusions of Dendritic and Cancer Cells |
title_fullStr | Cancer Vaccine by Fusions of Dendritic and Cancer Cells |
title_full_unstemmed | Cancer Vaccine by Fusions of Dendritic and Cancer Cells |
title_short | Cancer Vaccine by Fusions of Dendritic and Cancer Cells |
title_sort | cancer vaccine by fusions of dendritic and cancer cells |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2825547/ https://www.ncbi.nlm.nih.gov/pubmed/20182533 http://dx.doi.org/10.1155/2009/657369 |
work_keys_str_mv | AT koidoshigeo cancervaccinebyfusionsofdendriticandcancercells AT haraeiichi cancervaccinebyfusionsofdendriticandcancercells AT hommasadamu cancervaccinebyfusionsofdendriticandcancercells AT namikiyoshihisa cancervaccinebyfusionsofdendriticandcancercells AT ohkusatoshifumi cancervaccinebyfusionsofdendriticandcancercells AT gongjianlin cancervaccinebyfusionsofdendriticandcancercells AT tajirihisao cancervaccinebyfusionsofdendriticandcancercells |